- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | WINDTREE THERAPEUTICS INC /DE/ - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 07.01. | WINDTREE THERAPEUTICS INC /DE/ - 8-K, Current Report | - | SEC Filings | ||
| WINDTREE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree | 10 | FierceBiotech | ||
| 03.12.25 | Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | 246 | GlobeNewswire (Europe) | Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans... ► Artikel lesen | |
| 03.12.25 | Grosvenor Invests in Wint to Strengthen Water Intelligence and Sustainability Across Global Real Estate | 436 | PR Newswire | "Water risk and water waste are growing issues for the built environment, and Wint's technology will deliver clear value across our portfolio."BOSTON and LONDON, Dec. 3, 2025 /PRNewswire/... ► Artikel lesen | |
| 17.11.25 | Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee | 238 | GlobeNewswire (Europe) | The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed... ► Artikel lesen | |
| 14.11.25 | Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate | 473 | GlobeNewswire (Europe) | Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute... ► Artikel lesen | |
| 13.11.25 | Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company | 344 | GlobeNewswire (Europe) | Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree... ► Artikel lesen | |
| 05.08.25 | Windtree Therapeutics: Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients | 248 | GlobeNewswire (Europe) | Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses... ► Artikel lesen | |
| 29.07.25 | Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption | 247 | GlobeNewswire (Europe) | Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in... ► Artikel lesen | |
| 24.07.25 | Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy | 283 | GlobeNewswire (Europe) | Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July... ► Artikel lesen | |
| 17.07.25 | Windtree Therapeutics: NBC kassiert +100% über Nacht! | 876 | sharedeals.de | Es ist der völlige Wahnsinn, was sich seit Wochen wieder im No Brainer Club abspielt. Hunderte Mitglieder scheinen aus dem Partymodus kaum noch herauszukommen: Der jüngste Trading-Tipp liefert mindestens... ► Artikel lesen | |
| 17.07.25 | Pre-market Movers: Volcon, Bolt Projects, 22nd Century Group, Above Food Ingredients, Windtree Therapeutics | 1.118 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Volcon, Inc. (VLCN) is up over 161% at $24.11.
Bolt... ► Artikel lesen | |
| 16.07.25 | Windtree Therapeutics: Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions | 271 | GlobeNewswire (Europe) | WARRINGTON, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is excited to announce it has entered into a $60 million securities purchase... ► Artikel lesen | |
| 03.07.25 | Pre-market Movers: Global Interactive Technologies, MDB Capital, Empro Group, CapsoVision, Windtree Therapeutics | 1.538 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.55 A.M. ET).In the Green Global Interactive Technologies, Inc. (GITS) is up... ► Artikel lesen | |
| 02.07.25 | Windtree Therapeutics: Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure | 233 | GlobeNewswire (Europe) | 1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute... ► Artikel lesen | |
| 26.06.25 | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | 588 | GlobeNewswire (Europe) | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| 11.06.25 | Windtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug Candidate | 398 | GlobeNewswire (Europe) | Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,115 | +1,79 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| BB BIOTECH | 46,250 | +1,43 % | BB Biotech: "Wachstumsstarke Mid- und Small Caps bilden das Rückgrat unseres Portfolios": Mehr Einzelwerte und ... | ||
| MEDIGENE | 0,022 | -10,48 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| QIAGEN | 32,630 | +5,34 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| PAION | 0,100 | +23,60 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,424 | +0,66 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| AMGEN | 297,15 | +1,89 % | Mesoblast: Während Amgen und Novo Nordisk den Biotech-Hype treiben, arbeitet dieser Zelltherapie-Player am operativen Durchbruch | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 9,040 | +2,96 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| STRYKER | 258,30 | +1,49 % | Stryker launches new small bone power tool for orthopedic procedures | ||
| BIOGEN | 171,12 | +1,27 % | Biogen's Salanersen Wins FDA Breakthrough Therapy Designation For Spinal Muscular Atrophy Treatment | WESTON (dpa-AFX) - Thursday, Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular... ► Artikel lesen | |
| BIOFRONTERA | 2,490 | -4,96 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,650 | -1,12 % | HEIDELBERG PHARMA AG: Ruhe vor der nächsten Phase | ||
| ILLUMINA | 145,80 | -1,09 % | ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge? | ||
| CRISPR THERAPEUTICS | 49,700 | +10,63 % | CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential |
Das Unternehmen WINDTREE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,82 % bei einem Aktienkurs von 0,108 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WINDTREE THERAPEUTICS INC finden Sie auf Wallstreet Online.